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 ● Globally, there is a lack of pop-
ulation-based descriptive data 
for many leukaemia subtypes, 
of which there are more than 
30. This information is required 
to inform etiological hypothe-
ses, plan health-care services, 
and monitor the impact of ther-
apeutic change.
 ● Different subtypes of leukaemia 
dominate at different ages. For 
example, B-cell acute lympho-
blastic leukaemia is most com-
mon in children younger than 
15 years, and chronic lympho-
cytic leukaemia, myeloprolif-
erative neoplasms, and acute 
myeloid leukaemia are far more 
common at older ages.
 ● For reasons that are unknown, 
almost every leukaemia sub-
type has a male predominance.
 ● In high-income countries, sur-
vival rates vary widely from one 
subtype to another. The 5-year 
relative survival is more than 
80% for chronic lymphocytic 
leukaemia and chronic myeloid 
leukaemia but less than 20% 
for other subtypes, such as 
acute myeloid leukaemia.
 ● Increased understanding of 
pathogenesis has resulted in 
marked improvements in sur-
vival for some leukaemia sub-
types, including chronic my-
eloid leukaemia.
The leukaemias (literally “white 
blood”) comprise a heterogeneous 
group of more than 30 lymphoid and 
myeloid malignancies with diverse 
etiologies, treatment pathways, and 
outcomes [1]. They are classified by 
cell of origin (Fig. 5.20.1).
Leukaemias were first recog-
nized as a distinct entity in the 
1850s [2]. The taxonomy of leukae-
mias has changed markedly over 
time, as biological understanding 
of the similarities and differences 
between the various haematologi-
cal malignancies – leukaemias, 
lymphomas, and myelomas – and 
their relationship to the normal 
bone marrow and immune system 
has increased. However, contem-
porary population-based informa-
tion about the occurrence and out-
come for many leukaemia subtypes 
is sparse, and for some of the rarer 
entities is mostly non-existent.
This absence of data largely 
reflects the paradigm-changing 
nature of the WHO classification 
implemented in 2001 (the basis for 
the International Classification of 
Diseases for Oncology, third edition 
[ICD-O-3]), which, for the first time, 
incorporated genetic data with infor-
mation on immunology, morphology, 
and clinical parameters [3]. This re-
sulted not only in significant refine-
ments to previously defined catego-
ries but also in the addition of several 
new entities, including the myelodys-
plastic syndromes and myeloprolif-
erative neoplasms, which form part 
of the myeloid leukaemia spectrum. 
Critically, most of the neoplasms 
listed in the ICD-O-3 categories of 
myelodysplastic syndromes and my-
eloproliferative neoplasms still ap-
pear with a code beginning with “D” 
(neoplasms of unknown or uncer-
tain behaviour) in the International 
Statistical Classification of Diseases 
and Related Health Problems, 10th 
revision (ICD-10).
Such radical changes in classifi-
cation, together with the breadth of 
investigations required to implement 
the classification system (histol-
ogy, cytology, immunophenotyping, 
cytogenetics, flow cytometry, and 
clinical data), continue to pose sig-
nificant challenges for population-
based cancer registries; many strug-
gle to capture all diagnoses, and 
often continue to report using the 
traditional leukaemia grouping [4,5].
In 2018, there were an estimated 
437 000 new cases of leukaemia 
worldwide, and leukaemia was the 
15th most common cancer type, ac-
counting for 2.4% of all new cancer 
cases [6]. However, because many 
countries still do not have high-qual-
ity and representative cancer reg-
istration systems, examining global 
variation and trends over time is 
challenging for any cancer type; for 
leukaemias, the situation is exacer-
bated by the diagnostic challenges 
associated with identifying the vari-
ous leukaemia subtypes, coupled 
with the inconsistent implementation 
of the WHO classification [1,7,8]. 
Furthermore, even in countries with 
good cancer registration systems, 
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there is a lack of consistency in the 
policies applied to progressions and 
transformations (e.g. from myelo-
dysplastic syndromes to acute my-
eloid leukaemia [AML]); for exam-
ple, the United States Surveillance, 
Epidemiology, and End Results 
(SEER) programme has different 
rules to the European Network of 
Cancer Registries [9,10].
In low-income countries, where 
mortality and morbidity from infec-
tions and nutritional conditions are 
often high, diagnosing leukaemia 
presents additional challenges. 
The symptoms of many types of 
leukaemia are broadly similar to 
those of infectious and/or para-
sitic illnesses, and the diagnostic 
expertise and/or technologies re-
quired to enable leukaemia to be 
distinguished from background in-
fections are often lacking.
Descriptive epidemiology
Good-quality population-based de-
scriptive data are required not 
only to inform etiological hypoth-
eses and plan health-care services 
but also to monitor the impact of 
therapeutic change in the general 
population. This need is particu-
larly pertinent in fast-moving ar-
eas like haemato-oncology, where 
treatment protocols are subject to 
rapid change, and “gold standard” 
randomized controlled trials, which 
tend to be conducted almost exclu-
sively in higher-income countries, 
are frequently restricted to specific 
patient subgroups, often compris-
ing younger people with fewer co-
morbidities. Furthermore, in some 
countries, particularly low-income 
countries and/or those where uni-
versal health coverage is lacking, 
the likelihood of both treatment and 
trial entry often varies with socio-
economic status, sex, and ethnicity.
In recent years, there has been 
an increasing recognition that sci-
entific progress is being impeded by 
the lack of reliable population-based 
incidence and survival data on the 
various leukaemia subtypes [11]. 
This has led to improvements in na-
tional cancer registration procedures 
as well as the development of sev-
eral specialist registries [12,13]. One 
such source is the United Kingdom 
Haematological Malignancy Re-
search Network (HMRN; https://
www.hmrn.org), which since 2004 
has collated detailed information on 
all newly diagnosed haematologi-
cal malignancies arising in a popu-
lation of about 4 million [14]. The 
HMRN data for the 12 years from 
September 2004 to August 2016 
(n = 29 329) for the major subtypes 
(Fig. 5.20.2) illustrate where the leu-
kaemias sit within the broad WHO 
ICD-O-3 cell-of-origin haematologi-
cal malignancy spectrum.
The leukaemias account for 
about 40% of all haematological ma-
lignancies. They comprise all my-
eloid subtypes and several lymphoid 
subtypes. The main leukaemia 
subtypes are shown in Fig. 5.20.3. 
Mature B-cell chronic lymphocytic 
leukaemia (CLL) is the largest cate-
gory, followed by the myeloprolifera-
tive neoplasms, the AMLs, and the 
myelodysplastic syndromes.
Historically, when CLL cells 
were found in lymph nodes rather 
than in peripheral blood, the dis-
ease was termed small lymphocytic 
lymphoma. The different names 
reflected differences in disease 
spread rather than in origin. For 
research purposes, CLL is increas-
ingly grouped with other mature 
B-cell malignancies, both lympho-
mas and myelomas, and/or with 
the non-Hodgkin lymphomas, both 
T-cell and B-cell; the same is true 
for hairy cell leukaemia, which also 
has a mature B-cell origin [15,16]. 
However, most population-based 
registries still include CLL and hairy 
cell leukaemia in their “all leukae-
mia” category [4,11].
For information and complete-
ness, data on monoclonal B-cell 
lymphocytosis, which has an 
ICD-O-3 behaviour code of 1 (and 
is not listed in ICD-10), are also in-
cluded in Fig. 5.20.3. Monoclonal 
B-cell lymphocytosis is defined by 
a monoclonal B-cell count of less 
than 5 × 109/L in peripheral blood 
[1]. Because about 75% of cases 
have a CLL phenotype, monoclonal 
FUNDAMENTALS
 ■ Originating in blood-forming 
tissues, usually the bone mar-
row, the leukaemias comprise 
a heterogeneous group of lym-
phoid and myeloid malignan-
cies. This simple topographic 
categorization – cancer in the 
blood – reflects the pattern of 
spread rather than the origin.
 ■ The 2001 WHO classification 
of haematological malignan-
cies, which groups cancers 
according to their cell of origin, 
was adopted into worldwide 
clinical practice but did not 
have an immediate effect on 
population-based epidemio-
logical research. Increasing 
recognition that the lack of 
data on clinically meaningful 
groups was impeding scientific 
progress has led to recent im-
provements in national cancer 
registration procedures as well 
as the development of special-
ist registries.
 ■ Although the majority of 
leukaemia subtypes do not 
appear to have major environ-
mental determinants, a few 
well-established risk factors 
continue to produce strong 
associations, for example 
cytotoxic chemotherapy and/
or radiotherapy and acute 
myeloid leukaemia/myelodys-
plastic syndromes.
 ■ Knowledge relating to ge-
netic determinants has 
increased markedly over the 
past 5 years. The number of 
predisposition syndromes 
recognized to be associ-
ated with certain leukaemia 
subtypes is increasing, and a 
chapter on myeloid neoplasms 
with germline predisposition 
is included in the most recent 
WHO classification.
 ■ The leukaemias have led 
the field of cancer geno-
mics. Since the advent of the 
first targeted cancer therapy 
(tyrosine kinase inhibitors), 
advances in molecular biology 
and therapy have continued 
to transform the landscape for 
several – but by no means all – 
leukaemia subtypes.
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B-cell lymphocytosis is increasingly 
being studied with a view to increas-
ing the understanding of pathogen-
esis of CLL (defined by a monoclo-
nal B-cell count of ≥ 5 × 109/L with 
CLL morphology and phenotype).
The overall incidence of leukae-
mia, like that of many other types of 
cancer, increases with increasing 
age, and the incidence rate is high-
er in men than in women. However, 
in contrast to many other cancer 
types, leukaemias can occur at any 
age, and different subtypes domi-
nate at different ages. The hetero-
geneity of the various leukaemia 
subtypes (excluding monoclonal 
B-cell lymphocytosis) is illustrated 
in Fig. 5.20.4, which distributes the 
data by age at diagnosis and sex.
Acute lymphoblastic leukaemias 
(ALL), notably B-cell ALL, which 
accounts for less than 4% of the 
total, predominate in children youn-
ger than 15 years, an age group in 
which some leukaemia subtypes 
are often rare or non-existent. In 
contrast, at older ages, CLL, the 
myeloproliferative neoplasms, and 
the AMLs are far more common 
(Fig. 5.20.4). Variations with sex 
are also marked; the overall male 
predominance is evident across the 
full age spectrum and the main di-
agnostic subtypes. 
Additional differences are evident 
within subtypes [17], as illustrated 
in Fig. 5.20.5, which presents sex 
rate ratios for myelodysplastic syn-
dromes and AML. Myelodysplastic 
syndrome with deletion of chromo-
some 5q has a strong female pre-
dominance, in contrast to the other 
subtypes of myelodysplastic syn-
drome. AML with myelodysplasia-
related changes has a strong male 
predominance, whereas AML with 
MLL rearrangement is more com-
mon in females.
Risk factors
Like all diseases, the leukaemias 
have both genetic and environmen-
tal determinants to their etiology, 
and the relative contribution of each 
varies from one subtype to another.
With respect to environmental ex-
posures, relatively little has changed 
in the past 5 years; well-established 
risk factors continue to produce 
strong associations but explain only 
a small proportion of the total burden 
of disease. Examples of such asso-
ciations include those with cytotoxic 
chemotherapy, benzene, ionizing 
radiation, and viral infections such 
as human T-cell lymphotropic virus 
type 1 (HTLV-1), which is a neces-
sary but not sufficient cause of the 
comparatively rare adult T-cell leu-
kaemia/lymphoma (see Chapter 2.2). 
HTLV-1 causes leukaemia in about 
5% of people infected with the virus. 
Although HTLV-1 is endemic in parts 
of Japan, South America, Papua New 
Guinea, Africa, and the Middle East, 
it is hardly ever found elsewhere.
With respect to broader envi-
ronmental associations, systematic 
trends with frequently used proxies 
of exposure are rarely observed 
Fig. 5.20.1. Overview of haematopoiesis. Leukaemias are classified by cell of origin.
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for leukaemias, in contrast to many 
other cancer types. For example, 
in high-income countries the inci-
dence of several common cancer 
types tends to vary with regularly 
used markers of socioeconomic 
status or lifestyle, including educa-
tion level, income, and deprivation 
level, for reasons that are related 
either to etiology – exemplified by 
lung cancer and smoking, or cervi-
cal cancer and human papillomavi-
rus (HPV) infection – or to detec-
tion, as illustrated by colon cancer 
and screening. The consistency of 
such observations often helps to 
target public health interventions 
and policies that aim either to pre-
vent the development of disease 
(see Chapter 6.1) or to detect it at 
an early stage (see Chapter 6.6).
However, for the leukaemias, 
coherent patterns of this type are 
rarely observed. Findings from epi-
demiological studies examining the 
potential etiological role of specific 
risk factors, such as exposure to 
antibiotics, non-ionizing radiation, 
or hair dyes, often produce results 
that are weak and inconsistent. An 
extensive up-to-date review of all 
the evidence relating to the envi-
ronmental determinants of leukae-
mia in children and adults can be 
found in the latest edition of Cancer 
Epidemiology and Prevention [18].
As with environmental deter-
minants, certain genetic features 
that predispose towards leukaemia 
have long been known. Perhaps 
the most notable is male sex, 
which is generally associated with 
an increased risk across the age 
spectrum (Fig. 5.20.4). In addition, 
certain congenital disorders are 
strongly associated with the subse-
quent development of the acute leu-
kaemias, usually those occurring 
in children, adolescents, or young 
adults. Examples are the associa-
tion of Down syndrome with AML 
and ALL and of Fanconi anaemia 
and other bone marrow failure syn-
dromes with myelodysplastic syn-
dromes and AML.
In contrast to knowledge about 
environmental determinants, knowl-
edge relating to the genetic deter-
minants of several leukaemia sub-
types has increased markedly over 
the past 5 years. This increase is, 
at least in part, due to the advent of 
new genomic technologies and their 
growing accessibility to the wider 
scientific community. As a result, the 
number of predisposition syndromes 
recognized to be associated with 
certain leukaemia subtypes, particu-
larly (but not exclusively) those of the 
myeloid lineage, has increased con-
siderably. Knowledge in this area is 
advancing rapidly. A chapter on my-
eloid neoplasms with germline pre-
disposition (inherited and de novo) 
is, for the first time, included in the 
Fig. 5.20.2. Diagnostic distribution of haematological malignancies classified by the International Classification of Diseases for 
Oncology, third edition (ICD-O-3). Data from the Haematological Malignancy Research Network (HMRN) for 2004–2016 (n = 29 329). 
DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; NOS, not otherwise specified.
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most recent WHO classification, and 
associations between genetic condi-
tions and lymphoid leukaemias, no-
tably B-cell ALL, are also discussed 
in the relevant chapters [1].
Genomics, survival, and 
treatment
The leukaemias have led the field of 
cancer genomics. In the 1960s, the 
Philadelphia translocation was dis-
covered in chronic myeloid leukae-
mia (CML), a subtype of myelopro-
liferative neoplasms. This discovery 
eventually resulted in the develop-
ment of the first targeted therapy in 
cancer, a BCR-ABL tyrosine kinase 
inhibitor, which has transformed 
outcomes in CML [19].
Chromosomal analysis, under-
taken through either classical or 
molecular techniques, has been 
part of routine clinical practice 
for many decades [1]. However, 
these methods have limitations. 
Conventional cytogenetics are lim-
ited to detecting structural changes 
at a chromosome level, whereas 
smaller abnormalities such as point 
mutations are not detectable, and 
molecular cytogenetics can only be 
targeted at known abnormalities.
Accordingly, new techniques that 
have been developed in the past 
15 years are increasingly being used 
for the diagnosis, classification, and 
prognostication of the leukaemias. 
These include DNA sequencing and 
array-based platforms with next-
generation sequencing, which cur-
rently provides the greatest genomic 
resolution (see Chapter 3.2). Recent 
studies using these techniques are 
revealing the complexity of many 
leukaemia subtypes [20–23], many 
of which – unlike the single chromo-
somal translocation and resulting 
aberrant fusion protein in CML – 
have complex pathogenic pathways. 
Although next-generation sequenc-
ing and other techniques are rapidly 
becoming part of routine diagnostic 
practice in some settings, the incor-
poration of this information in other 
settings, particularly in low-income 
countries, remains challenging.
The scientific advances that 
have led to improvements in sur-
vival for some leukaemia subtypes 
are a major success story. In high-
income countries, survival rates for 
paediatric B-cell ALL now exceed 
90%, and survival rates for acute 
promyelocytic leukaemia, a subtype 
of AML, are about 80%. Tyrosine 
kinase inhibitors have transformed 
CML from a comparatively rare fa-
tal cancer to a long-term condition 
Fig. 5.20.3. Diagnostic distribution of leukaemias (including monoclonal B-cell lymphocytosis) classified by the International 
Classification of Diseases for Oncology, third edition (ICD-O-3). Data from the Haematological Malignancy Research Network 
(HMRN) for 2004–2016 (n = 11 231).
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with a survival rate that approaches 
that of the general population. Such 
progress has redirected the re-
search efforts to other types of leu-
kaemia, and to other cancer types.
However, despite these improve-
ments, the outlook for older people 
and those with aggressive subtypes 
remains poor. Contemporary esti-
mates of 5-year overall survival and 
relative survival from the HMRN 
population-based patient cohort 
are shown in Fig. 5.20.4, both by 
age strata for all subtypes com-
bined and by major subtype by all 
ages combined. The corresponding 
relative survival curves are shown 
in Fig. 5.20.6.
Although some subtypes of 
AML are potentially curable with 
intensive chemotherapy, over the 
past three decades there has been 
little improvement for the majority 
of AML patients. The 5-year rela-
tive survival for AML in the HMRN 
population-based data is 13.2%. 
For AML, the median age at diag-
nosis is about 70 years. Although 
the frequency of curative therapy is 
relatively high in younger patients, 
who often comprise the focus of 
clinical trials involving ALLs as well 
as AMLs, the inability of some pa-
tients, notably older patients, to tol-
erate intensive chemotherapy regi-
mens remains problematic.
The increased application of 
genomic technologies is leading to 
the development of new targeted 
agents, including monoclonal anti-
bodies. However, at present, most 
of these agents still need to be used 
in conjunction with intensive che-
motherapy, so little progress has 
been made to date for the treatment 
of patients who cannot tolerate 
such regimens [24].
In contrast, the outlook for pa-
tients with more indolent leukae-
mias, including CLL (5-year relative 
survival, 84.1%) and the myelopro-
liferative neoplasms (5-year relative 
survival, 92.1%), is relatively good, 
despite the fact that these cancers 
are currently incurable. The path-
ways of patients with these more 
chronic cancers often follow a remit-
ting–relapsing course, with patients 
being monitored until chemothera-
py treatment is required, and some 
never receiving treatment at all.
Prevention and early 
detection
In recent decades, advances in mo-
lecular biology and therapy have 
transformed the landscape for sev-
eral leukaemia subtypes. However, 
in general this progress has not 
been matched by similar insights 
into the etiological determinants of 
the majority of leukaemias. In such 
circumstances, the development of 
preventive strategies that will af-
fect the total burden of leukaemia 
Fig. 5.20.4. Incidence proportions of leukaemias (excluding monoclonal B-cell lymphocytosis) distributed by subtype within age 
strata, age-standardized (world, 2000–2025) rates per 100 000, and 5-year overall survival (OS) and relative survival (RS). Sex 
rate ratio is male rate divided by female rate. Data from the Haematological Malignancy Research Network (HMRN) for 2004–2016, 
followed up September 2018.
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is challenging. However, it is clear 
that reduction in population expo-
sures to well-known leukaemogenic 
agents such as polycyclic aromatic 
hydrocarbons should be pursued. 
In addition, radiological diagnostic 
and therapeutic procedures involv-
ing ionizing radiation should be 
used only when clinically required, 
and at the lowest possible doses.
With respect to the potential 
impact on high-risk groups, more 
careful monitoring of individuals 
with recognized leukaemia predis-
position syndromes or other genetic 
susceptibilities is one area where 
improvements could be made. For 
example, the onset of bone mar-
row failure, a prelude to AML, could 
perhaps be detected at an earlier 
stage, enabling pre-emptive hae-
matopoietic stem cell transplanta-
tion to be undertaken.
However, in situations where 
primary prevention is not possible, 
early detection and improved treat-
ments tend to be the major focus. 
In this respect, the landscape for 
the leukaemias is changing rapidly, 
with new diagnostic technologies 
and less toxic targeted novel agents 
emerging, providing considerable 
promise for the future.
Fig. 5.20.5. Sex rate ratios (male rate divided by female rate) for subtypes of myelo-
dysplastic syndromes and acute myeloid leukaemia (AML).
Fig. 5.20.6. Relative survival curves for leukaemias classified by the International Classification of Diseases for Oncology, third edition 
(ICD-O-3). Data from the Haematological Malignancy Research Network (HMRN) for 2004–2016, followed up September 2018.
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